Ro Deepens Novo Nordisk Partnership With Lower-Cost Wegovy Plans and Expanded GLP-1 Offering

New updates have been reported about Ro.

Ro is cutting out-of-pocket costs for patients using Wegovy under its collaboration with Novo Nordisk, offering cash-pay customers savings of up to $1,200 per year on the injectable pen and $600 per year on the pill through new three-, six-, and 12‑month prepaid plans, alongside forthcoming lower-priced Ro Body membership tiers that bundle medication access with ongoing virtual care. CEO Zach Reitano framed affordability as the core barrier to adoption of GLP‑1 therapies and positioned Ro’s direct‑to‑patient platform as a scalable distribution model for FDA‑approved obesity treatments.

The move builds on Ro’s April 2025 agreement with Novo Nordisk, under which Ro helped launch the Wegovy pill nationally on day one of market availability, contributing to one of the strongest rollouts for an oral GLP‑1 weight‑loss drug and reinforcing Ro’s role as a channel for high-demand metabolic therapies. In April, Ro will introduce discounted Body membership options that include 24/7 messaging, progress and side‑effect monitoring, and one‑on‑one coaching, while continuing to steer patients to the lowest total cost via its GLP‑1 Insurance Checker, which has already been used by more than 2 million people to compare cash pricing with insurance coverage and optimize their payment strategy.